Two Phase 3 clinical trials that involved more than 1,000 adults have significantly strengthened the case for Eli Lilly's experimental GLP-1-based drug retatrutide to gain FDA approval for both weight loss and relief from knee osteoarthritis (OA).

For people with painful knee osteoarthritis (OA) who are overweight or have obesity, everyday activities such as walking, climbing stairs and standing up from a chair can be difficult. In two Northwestern ...